New shingles vaccine safety and immune response study
Treatments studied
Part of Infections clinical trials.
This study tests a new shingles vaccine for people 40 and older. It looks at safety, how well the body responds, and whether it can prevent shingles.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 40 years old or older.
- You have never had shingles or a shingles/chickenpox vaccine before.
- You are generally healthy or have stable, well-managed health conditions.
- You do not have a weakened immune system or take medicines that suppress immunity.
- You agree to use effective birth control if you could become pregnant or father a child, for at least 90 days after the last shot.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new shingles vaccine to see how well it prevents shingles in adults aged 40 and older. It aims to help those who have not had shingles recently or been vaccinated against it before.
This study tests a new shingles vaccine to make sure each batch works the same way. If you are 40 or older and have never had shingles or the shingles vaccine, you may qualify.
This trial tests a new shingles vaccine to see if it's safe and helps the body build immunity. It is for healthy adults aged 50 and older who have not had shingles before.
This trial tests a new mRNA vaccine to prevent shingles (herpes zoster). It checks if the vaccine is safe and helps your body build immunity. It's for adults aged 40 or older (phase 1) or 50+ (phase 2).
This study tests an experimental shingles vaccine in adults aged 40 and older. It aims to see if the vaccine is safe and helps your body build immunity against shingles.
This trial tests a new shingles vaccine in healthy adults aged 50 to 65. Shingles can cause a painful rash, and the vaccine aims to prevent it.
Hear when a new Herpes Zoster trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.